A Phase I Study of GZR18 Injection in Obese/Overweight Subjects
Status:
COMPLETED
Trial end date:
2023-08-14
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study. A sequential design is used in this trial with a single dose escalation climb test, to investigate the safety, tolerability, and PK/PD characteristics of GZR18 injection in Chinese obese/overweight subjects.